BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875
This article was originally published in The Gray Sheet
Executive Summary
EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.
You may also be interested in...
Urologix Doubles Presence In BPH Treatment Via $20 Mil. Prostatron Buy
Addition of Edap's Prostatron transurethral microwave thermotherapy (TUMT) system for treatment of benign prostatic hyperplasia (BPH) doubles Urologix' market presence in the BPH treatment area, the firm says. Urologix also expects the total number of cooled microwave thermotherapy procedures performed "to double in the next year" due to expanded market acceptance of the treatment.
Urologix Doubles Presence In BPH Treatment Via $20 Mil. Prostatron Buy
Addition of Edap's Prostatron transurethral microwave thermotherapy (TUMT) system for treatment of benign prostatic hyperplasia (BPH) doubles Urologix' market presence in the BPH treatment area, the firm says. Urologix also expects the total number of cooled microwave thermotherapy procedures performed "to double in the next year" due to expanded market acceptance of the treatment.
Urologix Shakes Off Reimbursement Woes; Stock Is Up Nearly 80% In July
Urologix' announcement that its Targis microwave system likely will be reimbursed on par with other minimally invasive therapies for benign prostatic hyperplasia under the Health Care Financing Administration's physician fee schedule signaled that the firm's payment problems may finally be coming to an end. The issue ended July up 78.5%.